http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
BioLife Solutions (BLFS), Kite Pharma (KITE) Enter Long-Term CryoStor Supply Agreement
-
Kite Pharma Completes Enrollment of All Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in Pivotal Multi-Center Phase 2 Study of KTE-C19 (ZUMA-1)
-
Kite Pharma Opens State-of-the-Art T-Cell Therapy Manufacturing Facility
-
Kite Pharma (KITE) Enters Agreement with NCI for TCR Therapies Development
-
Kite Pharma Expands Development of T-Cell Receptor (TCR) Therapies Targeting HPV-Associated Cancers in Partnership with the National Cancer Institute (NCI)
-
Goldman M&A Basket in Focus After Predicting LinkedIn (LNKD); (TWTR) (BLUE) (TRIP), Others Added
-
Kite Pharma to Highlight Key Data from CAR T-Cell Therapy Pipeline in Oral Presentations at the 2016 European Hematology Association (EHA) Annual Congress
-
Kite Pharma (KITE) Will Present SCHOLAR-1 Data in Chemorefractory DLBCL at ASCO
-
Kite Pharma (KITE) to Present Positive KTE-C19 ZUMA-1 Data at ASCO: Three Complete Remissions Ongoing
-
Kite Pharma Announces the First Meta-Analysis of Outcomes in Chemorefractory Diffuse Large B-Cell Lymphoma (SCHOLAR-1)
-
Kite Pharma Presents Ongoing Complete Responses at 9 Months in Phase 1 of ZUMA-1 in Patients with Chemorefractory Non-Hodgkin Lymphoma
-
Kite/NCI Anti-CD19 CAR T-Cell Therapy Demonstrates Durable Complete Remissions in Advanced Non-Hodgkin Lymphoma
-
Kite Pharma (KITE), Cell Design Labs Enter Research Collaboration for Next-Gen CAR Product Candidates
-
Kite Pharma and Cell Design Labs Announce Exclusive Research Collaboration Using Molecular ‘On/Off Switches’ for CAR T-Cell Immunotherapies
-
Kite Pharma (KITE) Receives Access to PRIME Regulatory Support for KTE-C19 in Treatment of Chemorefractory DLBCL
-
Kite Pharma Granted Access to Priority Medicines (PRIME) Regulatory Support for KTE-C19 in the Treatment of Chemorefractory Diffuse Large B-Cell Lymphoma (DLBCL)
-
Kite Pharma to Highlight Key Data from Engineered CAR T Cell Therapy Pipeline at the 2016 American Society of Clinical Oncology Annual Meeting
-
Kite Pharma to Present at June 2016 Investor Conferences
-
Kite Pharma (KITE) Names New CFO;
-
Kite Pharma Expands Leadership Team, Appoints Paul L. Jenkinson as Chief Financial Officer
-
Kite Pharma Reports First Quarter 2016 Financial Results
-
Kite Pharma to Report First Quarter 2016 Financial Results on May 9, 2016
-
Kite Pharma Announces FDA Orphan Drug Designations for KTE-C19 in Five Additional Indications
-
Kite Pharma (KITE) to Present at ASGCT 2016; Will Includes KTE-C19 Data
-
Kite Pharma Announces Presentations at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
-
Kite Pharma Commends Scientific Advisory Board Members on Awards Received from the American Association of Cancer Research (AACR)
-
Kite Pharma (KITE) to Present Engineered Cell Therapy Data at AACR 2016; Includes KTE-C19
-
Kite Pharma Announces Key Presentations on KTE-C19 and Engineered Cell Therapy Pipeline Programs at the Annual Meeting of the American Association for Cancer Research (AACR)
-
Kite Pharma (KITE), Genentech Enter Collaboration to Evaluate KTE-C19 + Atezolizumab in NHL (RHHBY)
-
Kite Pharma Announces Clinical Collaboration to Evaluate Two Novel Immunotherapies for Patients with Non-Hodgkin Lymphoma
-
Kite Pharma (KITE) Announces Two Oral Presentations and Two Poster Presentations at AACR
-
Kite Pharma Announces Clinical and Manufacturing Updates on KTE-C19 and MAGE-A3 Product Candidates at the Annual Meeting of the American Association for Cancer Research (AACR)
-
Kite Pharma Deepens Cell Manufacturing and Operations Expertise with Appointment of Tim Moore
-
Kite Pharma to Present at March 2016 Investor Conferences
-
Kite Pharma Reports Fourth Quarter and Full-Year 2015 Financial Results
-
Kite Pharma Augments Commercial Leadership Team
-
Kite Pharma to Report Fourth Quarter and Full Year 2015 Financial Results on February 29, 2016
-
Kite Pharma to Participate in the 2016 RBC Capital Markets Global Healthcare Conference
-
Notable Analyst Rating Changes 2/2: (MS) (NFLX) (TJX) Upgraded; (AR) (LOGI) (TWTR) Downgraded
-
Pre-Open Stock Movers 02/02: (HNSN) (KORS) (GOOGL) (GOOG) Higher; (ZINC) (IDTI) (HEAR) Lower (more...)
-
Kite Pharma (KITE) Unit Enters TCR Product Candidate Research, License Agreement with LUMC
-
Kite Pharma and Leiden University Medical Center Sign Research and License Agreement for T Cell Receptors Targeting HPV-Associated Cancers
-
Kite Pharma (KITE), NCI Expand Clinical and Research Partnership
-
Kite Pharma Expands Its Clinical and Research Partnership With the National Cancer Institute (NCI) for Next-Generation CAR Programs to Treat B-Cell Malignancies
-
Kite Pharma to Present at the 34th Annual J.P. Morgan Healthcare Conference
-
Kite Pharma (KITE) Names Shawn Tomasello CCO
-
Kite Pharma Appoints Industry Leader Shawn Cline Tomasello as Chief Commercial Officer
-
Kite Pharma (KITE) Presents Posters on anti-CD19 CAR T-Cell Therapy in NHL
-
Kite Pharma Announces Clinical Biomarker Results of Anti-CD19 CAR T Cell Therapy at the 57th American Society of Hematology Annual Meeting (ASH)
-
Kite Pharma (KITE) Announces Results, Biomarker Data from KTE-C19 ZUMA-1 Phase 1 in NHL
